Insufficient evidence to deny antibiotic treatment to chronic Lyme disease patients

Medical Hypotheses

Volumn 72, Issue 6, 2009, Pages 688-691

  Cameron, Daniel J ^a  

^a First Medical Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFTRIAXONE; PLACEBO;

ANAPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COST OF ILLNESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HUMAN; LYME DISEASE; MIXED INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; THERAPY DELAY; THROMBUS;

ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; LYME DISEASE; PREVALENCE; REFUSAL TO TREAT;

EID: 62949228383     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.01.017     Document Type: Article

References (39)

1. Lyme disease - United States. MMWR Morb Mortal Wkly Rep 2002;51(2):29-31.
2. Smith R., O'Connell S., and Palmer S. Lyme disease surveillance in England and Wales, 1986-1998. Emerg Infect Dis 6 4 (2000) 404-407
3. Bacon R.M., Kugeler K.J., and Mead P.S. Surveillance for Lyme disease - United States, 1992-2006. MMWR Surveill Summ 57 10 (2008) 1-9
4. Lyme disease - United States, 2001-2002. MMWR Morb Mortal Wkly Rep 2004;53(17):365-9.
5. ; p. 290 [accessed 12.4.08].
6. Asch E.S., Bujak D.I., Weiss M., Peterson M.G., and Weinstein A. Lyme disease: an infectious and postinfectious syndrome. J Rheumatol 21 3 (1994) 454-461
7. Shadick N.A., Phillips C.B., Logigian E.L., Steere A.C., Kaplan R.F., Berardi V.P., et al. The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study. Ann Int Med 121 8 (1994) 560-567
8. Fallon B.A., Keilp J.G., Corbera K.M., Petkova E., Britton C.B., Dwyer E., et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 70 13 (2008) 992-1003
9. Klempner M.S. Controlled trials of antibiotic treatment in patients with post-treatment chronic Lyme disease. Vector Borne Zoonotic Dis 2 4 (2002) 255-263
10. Krupp L.B., Hyman L.G., Grimson R., Coyle P.K., Melville P., Ahnn S., et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 60 12 (2003) 1923-1930
11. Klempner M.S., Hu L.T., Evans J., Schmid C.H., Johnson G.M., Trevino R.P., et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 345 2 (2001) 85-92
12. Cameron DJ. Clinical trials validate the severity of persistent Lyme disease symptoms. Med Hypotheses 2008.
13. Zhang X., Meltzer M.I., Pena C.A., Hopkins A.B., Wroth L., and Fix A.D. Economic impact of Lyme disease. Emerg Infect Dis 12 4 (2006) 653-660
14. Cameron D., Gaito A., Harris N., Bach G., Bellovin S., Bock K., et al. Evidence-based guidelines for the management of Lyme disease. Expert Rev Anti Infect Ther 2 Suppl. 1 (2004) S1-13
15. Halperin J.J., Shapiro E.D., Logigian E., Belman A.L., Dotevall L., Wormser G.P., et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 69 1 (2007) 91-102
16. Steere A.C., Green J., Schoen R.T., Taylor E., Hutchinson G.J., Rahn D.W., et al. Successful parenteral penicillin therapy of established Lyme arthritis. N Engl J Med 312 14 (1985) 869-874
17. Krause P.J., Telford III S.R., Spielman A., Sikand V., Ryan R., Christianson D., et al. Concurrent Lyme disease and babesiosis. Evidence for increased severity and duration of illness. JAMA 275 21 (1996) 1657-1660
18. Donta S.T. Macrolide therapy of chronic Lyme disease. Med Sci Monit 9 11 (2003) PI136-PI142
19. Donta S.T. Tetracycline therapy for chronic Lyme disease. Clin Infect Dis 25 Suppl. 1 (1997) S52-S56
20. Cameron D. Severity of Lyme disease with persistent symptoms. Insights from a double-blind placebo-controlled clinical trial. Minerva Med 99 5 (2008) 489-496
21. Feder Jr. H.M., Johnson B.J., O'Connell S., Shapiro E.D., Steere A.C., Wormser G.P., et al. A critical appraisal of "chronic Lyme disease". N Engl J Med 357 14 (2007) 1422-1430
22. Johnson L., and Stricker R.B. Treatment of Lyme disease: a medicolegal assessment. Expert Rev Anti Infect Ther 2 4 (2004) 533-557
23. Cameron D.J. An appraisal of "chronic Lyme disease". N Engl J Med 358 4 (2008) 429-430 [author reply 430-421]
24. Kish M.A. Guide to development of practice guidelines. Clin Infect Dis 32 6 (2001) 851-854
25. Wormser G.P., Dattwyler R.J., Shapiro E.D., Halperin J.J., Steere A.C., Klempner M.S., et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 43 9 (2006) 1089-1134
26. UnitedHealthCare. Treatment of chronic and recurrent Lyme disease. ; [accessed 12.23.08].
27. Cigna. Medical coverage policy Lyme disease treatment. ; [accessed 12.23.08].
28. Aetna: Clinical Policy Bulletin. Lyme disease and other tick-borne diseases. ; [accessed 12.23.08].
29. BlueCross BlueShield of Wisconsin parenteral antibiotics for the treatment of Lyme disease. ; [accessed 12.23.08].
30. Cameron D.J. Generalizability in two clinical trials of Lyme disease. Epidemiol Perspect Innov 3 (2006) 12
31. Dattwyler R.J., Wormser G.P., Rush T.J., Finkel M.F., Schoen R.T., Grunwaldt E., et al. A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wien Klin Wochenschr 117 11-12 (2005) 393-397
32. Logigian E.L., Kaplan R.F., and Steere A.C. Chronic neurologic manifestations of Lyme disease. N Engl J Med 323 21 (1990) 1438-1444
33. Wahlberg P., Granlund H., Nyman D., Panelius J., and Seppala I. Treatment of late Lyme borreliosis. J Infect 29 3 (1994) 255-261
34. Logigian E.L., Kaplan R.F., and Steere A.C. Successful treatment of Lyme encephalopathy with intravenous ceftriaxone. J Infect Dis 180 2 (1999) 377-383
35. Krupp L.B., LaRocca N.G., Muir-Nash J., and Steinberg A.D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46 10 (1989) 1121-1123
36. Levy S.B. The 2000 Garrod lecture. Factors impacting on the problem of antibiotic resistance. J Antimicrob Chemother 49 1 (2002) 25-30
37. Cameron D.J. Consequences of treatment delay in Lyme disease. J Eval Clin Pract 13 3 (2007) 470-472
38. Swanson S.J., Neitzel D., Reed K.D., and Belongia E.A. Coinfections acquired from ixodes ticks. Clin Microbiol Rev 19 4 (2006) 708-727
39. Shrier I. Uncertainty about clinical equipoise. CMAJ 164 13 (2001) 1831 [author reply 1831-2]